Bioconvergence Market Report 2026

The bioconvergence market size has grown rapidly in recent years. It will grow from $158.2 billion in 2025 to $175.26 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to genomics research growth, digital health adoption, biotechnology funding expansion, advanced diagnostics demand, interdisciplinary research initiatives.

The bioconvergence market size is expected to see rapid growth in the next few years. It will grow to $263.67 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to personalized medicine acceleration, AI-enabled life sciences, bioengineering innovation, data-driven healthcare solutions, cross-industry collaborations. Major trends in the forecast period include integration of biology with engineering systems, expansion of precision medicine platforms, growing adoption of AI-driven drug discovery, increased use of bioinformatics solutions, convergence of digital and biological technologies.

The growing emphasis on personalized medicine is expected to propel the growth of the bioconvergence market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable precise identification of genetic variations and tailored treatments for individuals. Bioconvergence enhances personalized medicine by integrating advanced technologies with biological research, enabling more precise, individualized treatment plans tailored to a patient’s genetic and molecular profile. It improves healthcare outcomes by facilitating targeted therapies and reducing adverse effects. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the growing emphasis on personalized medicine is driving the growth of the bioconvergence market.

Major companies operating in the bioconvergence market are focusing on developing innovative products, such as integrated nanopore sequencing devices with onboard computing, to eliminate external computing dependencies, enable real-time data analysis, and streamline laboratory workflows. An integrated nanopore sequencing device with onboard computing is a self-contained benchtop system that performs DNA, RNA, and cDNA sequencing with built-in basecalling and analysis capabilities. For instance, in March 2024, Oxford Nanopore Technologies, a UK-based biotechnology company, launched the PromethION 2 Integrated (P2i) to democratize high-output nanopore sequencing for small and medium-sized research laboratories. This innovative bioconvergence tool enables on-device real-time basecalling using onboard NVIDIA Ampere architecture GPU, allowing researchers to generate up to 290 gigabases of data per flow cell, eliminate dependency on external computing infrastructure, and gain immediate biological insights through integrated MinKNOW software with plug-and-play functionality. The PromethION 2 Integrated is highly versatile, offering effective sequencing capabilities for diverse applications including whole-genome sequencing of large organisms, comprehensive metagenomic studies, and full-transcript-length RNA analysis by combining two independently addressable flow cells with integrated touchscreen control and 15 terabytes of onboard storage for improved workflow efficiency and data quality.

In November 2024, Quris-AI, an Israel- and US-based biotechnology company, acquired Nortis (Numa Biosciences, Inc.) for an undisclosed amount. Through this acquisition, Quris-AI strengthens its bioconvergence portfolio by incorporating Nortis’s Kidney-on-Chip microphysiology systems technology, which enables earlier detection of potentially harmful drug candidates through improved renal toxicity evaluation and pharmacokinetic forecasting, while enhancing the accuracy and efficiency of preclinical and clinical drug safety predictions. Nortis is a US-based biotechnology company engaged in bioconvergence.

Major companies operating in the bioconvergence market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Veolia Environnement S.A, Novartis AG, Eli Lilly and Company, Amgen Inc., HDR Inc., Ginkgo Bioworks, BICO Group AB, MeMed Diagnostics Ltd., Anima Biotech, Singota Solutions LLC, SetPoint Medical Corporation, Galvani Bioelectronics, Ezassi Inc., Tissue Dynamics Ltd., Sanara Ventures Ltd., BioConvergent Health LLC, Gradiant Bioconvergence Center.

North America was the largest region in the bioconvergence market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioconvergence market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioconvergence market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the bioconvergence market by increasing the cost of imported laboratory equipment, analytical instruments, and specialized software infrastructure. These impacts have been most pronounced in drug discovery and precision medicine segments, particularly in north america and europe. Asia-pacific technology providers have faced supply chain cost pressures. However, tariffs have supported domestic innovation ecosystems and localized platform development.

The bioconvergence market research report is one of a series of new reports that provides bioconvergence market statistics, including bioconvergence industry global market size, regional shares, competitors with a bioconvergence market share, detailed bioconvergence market segments, market trends and opportunities, and any further data you may need to thrive in the bioconvergence industry. This bioconvergence market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bioconvergence is the integration of biology with engineering, data science, and advanced technologies to drive innovation in healthcare, biotechnology, and life sciences. Its primary aim is to create smarter, more personalized, and more efficient solutions, including precision medicine, advanced diagnostics, and bioengineered products. Bioconvergence enables the development of faster, more cost-effective, and highly efficient therapies, devices, and platforms.

The main components of bioconvergence include devices, software, services, and platforms. Devices are tools or hardware that interact with biological systems, often combining biology, engineering, and digital technologies. Bioconvergence incorporates advanced technologies such as artificial intelligence, robotics, 3D printing, nanotechnology, synthetic biology, bioinformatics, and wearable devices. These technologies support a wide range of applications, including drug discovery, regenerative medicine, optogenetics, nanorobotics for targeted therapies, diagnostic and biosensing tools, bioelectronics, and precision medicine. The key end users of these innovations include pharmaceutical and biotechnology companies, contract research organizations, and other related sectors.

The bioconvergence market consists of revenues earned by entities by providing services such as personalized medicine development, biomedical data analysis, bioinformatics platforms, regenerative medicine solutions, diagnostic technology integration, and smart medical device engineering. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioconvergence market also includes sales of bioprinted tissues and organs, lab-on-a-chip devices, smart implants, bioengineered materials, and integrated diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.